Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Itama Ranoraya TbkISX:IRRA 84 3-Year ROIIC % is 1.97 as of Dec. 2025, which is 68% below its 10-year median of 6.25. GuruFocus rates ISX:IRRA with a GF Score™ of 84/100 and a GF Value™ of Rp540.53 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 113 Medical Distribution companies, PT Itama Ranoraya Tbk ranks worse than 52.21% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
PT Itama Ranoraya Tbk's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 1.97%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for PT Itama Ranoraya Tbk's 3-Year ROIIC % or its related term are showing as below:
ISX:IRRA's 3-Year ROIIC % is ranked worse than 52.21% of 113
companies
in the Medical Distribution industry
Industry Median: 2.2
vs ISX:IRRA: 1.97
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
PT Itama Ranoraya Tbk 3-Year ROIIC % Related Terms
PT Itama Ranoraya Tbk 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for PT Itama Ranoraya Tbk's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:IRRA vs MCK, COR, CAH: 3-Year ROIIC % Comparison
For the Medical Distribution subindustry, PT Itama Ranoraya Tbk's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Itama Ranoraya Tbk 3-Year ROIIC % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Itama Ranoraya Tbk's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where PT Itama Ranoraya Tbk's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
PT Itama Ranoraya Tbk (ISX:IRRA) has a 3-Year ROIIC % of 1.97 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on PT Itama Ranoraya Tbk and its competitors. This is 68% below median its historical median of 6.25. According to the industry distribution chart, PT Itama Ranoraya Tbk ranks #59 out of 113 companies in the Medical Distribution industry, placing it in the top 52.2%.
Is PT Itama Ranoraya Tbk's 3-Year ROIIC % too high?
PT Itama Ranoraya Tbk's current 3-Year ROIIC % of 1.97 is 68% below median its 10-year median of 6.25. The Medical Distribution industry median 3-Year ROIIC % is 2.20. PT Itama Ranoraya Tbk's value of 1.97 is 10.5% below this industry median. Based on the distribution chart, PT Itama Ranoraya Tbk ranks #59 out of 113 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, PT Itama Ranoraya Tbk has a GF Score™ of 84/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PT Itama Ranoraya Tbk's 3-Year ROIIC % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Itama Ranoraya Tbk ranks #59 out of 113 companies for 3-Year ROIIC %. This places PT Itama Ranoraya Tbk in the lower half of its industry. The industry median 3-Year ROIIC % is 2.20. PT Itama Ranoraya Tbk's value of 1.97 is 10.5% below this benchmark. While the company's 10-year median is 6.25 vs. the industry median of 2.20, PT Itama Ranoraya Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Distribution company?
The median 3-Year ROIIC % among Medical Distribution companies is 2.20, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Itama Ranoraya Tbk's current 3-Year ROIIC % of 1.97 is 10.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on PT Itama Ranoraya Tbk and its competitors. For the Medical Distribution industry, the median 3-Year ROIIC % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Itama Ranoraya Tbk's current 3-Year ROIIC % is 1.97, which is 68% below median its own 10-year median of 6.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Itama Ranoraya Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Itama Ranoraya Tbk (ISX:IRRA) is currently considered Possible Value Trap. The stock's GF Value™ is Rp540.53, compared to a current price of Rp374.00 — trading 30.8% below its estimated fair value. The current 3-Year ROIIC % is 1.97, which is 68% below median its 10-year median of 6.25 and 10.5% below the Medical Distribution industry median of 2.20. PT Itama Ranoraya Tbk's overall GF Score™ is 84/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For PT Itama Ranoraya Tbk (ISX:IRRA), the current 3-Year ROIIC % is 1.97 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Itama Ranoraya Tbk (ISX:IRRA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Itama Ranoraya Tbk stock appears to be undervalued.
The current stock price of Rp374.00 is trading 30.8% below its estimated GF Value™ of Rp540.53.
GuruFocus considers PT Itama Ranoraya Tbk to be Possible Value Trap.
Key valuation signals for ISX:IRRA:
3-Year ROIIC %: 1.97 (68% below median its 10-year median of 6.25)
GF Value™: Rp540.53 vs. price of Rp374.00 (30.8% below fair value)
Industry Position: 10.5% below the Medical Distribution median (#59 of 113)
No single metric tells the full story. See the ISX:IRRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Itama Ranoraya Tbk focuses on the trade and distribution of medical devices. The company distributes medical devices such as Oneject auto disable syringe, Abbott diagnostics, TerumoBCT, Ortho Clinical diagnostics and others. It business segment includes Vitro Diagnostic Products, Non-Electromedical Sterile Medical Devices, Electromedical Sterile Medical Devices and Other Segments. The key revenue generating segments of the company are In Vitro Diagnostic product.
84GF Score
Get the complete analysis for ISX:IRRA
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:IRRA has been successfully added to your 
